Pharmacology
Mechanism of Action
Ferric carboxymaltose forms a stable complex that protects the iron core from rapid free iron release. The carboxymaltose shell enables controlled release through reticuloendothelial uptake, transferrin loading, and eventual incorporation into haemoglobin — without the anaphylaxis risk associated with iron-dextran preparations.
1,000 mg
Maximum single-dose iron delivery
in 15-minute infusion
>1 g/dL
Haemoglobin rise
within 4 weeks post-infusion
0.1%
Serious adverse event rate
lower than iron dextran and sucrose
Neutral pH
Formulation pH 5.0–7.0
minimises vascular irritation
Approved Indications
Iron deficiency anaemia (IDA) in adults
IDA in pregnancy and postpartum
Chemotherapy-associated anaemia (with erythropoietin)
Pre-operative anaemia optimisation
Inflammatory bowel disease-associated IDA
Why Manufacture Ferric with Addams
Non-dextran matrix eliminates mandatory test dose requirement
Validated endotoxin levels <0.25 EU/mL per USP/Ph.Eur.
Stability validated at 25°C/60%RH for 24 months
In-house iron speciation testing for quality confirmation